President Trump has delivered a major victory for American families by securing a groundbreaking deal that will slash the cost of life-saving obesity medications while expanding Medicare coverage to millions of seniors who were previously denied access.
Story Highlights
- Trump negotiated directly with Big Pharma to cap Medicare copays at just $50 for obesity drugs like Ozempic.
- Eli Lilly and Novo Nordisk agreed to offer $245 dose pricing to state Medicaid programs nationwide.
- Medicare will now cover GLP-1 drugs for seniors with severe obesity and related health conditions.
- Deal bypasses bureaucratic red tape and delivers immediate relief to rural and underserved communities.
Trump Delivers Where Biden Failed on Drug Costs
President Trump announced the historic agreement on November 6, 2025, demonstrating the kind of decisive leadership that gets results for everyday Americans. While the previous administration tied itself in regulatory knots, Trump sat down with pharmaceutical giants Eli Lilly and Novo Nordisk and hammered out a deal that will save lives and money. Medicare enrollees will now pay just $50 copays for GLP-1 medications that previously cost hundreds or thousands of dollars monthly.
The agreement represents a complete reversal of Medicare’s longstanding exclusion of weight-loss medications. Trump’s approach prioritized results over bureaucracy, securing immediate implementation rather than years of regulatory delays. Health Secretary Robert F. Kennedy Jr. joined the announcement, emphasizing how this deal will particularly benefit Americans in rural areas and food deserts who have been abandoned by the healthcare establishment.
Big Pharma Bends to America First Negotiations
Trump’s negotiating prowess forced major concessions from pharmaceutical companies that have long exploited American patients with sky-high drug prices. Eli Lilly and Novo Nordisk agreed to offer their GLP-1 medications to all state Medicaid programs at $245 per dose, a fraction of current market rates. This America First approach puts patients before pharmaceutical profits, something the globalist establishment has consistently failed to achieve.
The deal covers seniors with severe obesity, those overweight with prediabetes or cardiovascular disease, and patients with obesity plus advanced kidney disease, heart failure, or uncontrolled hypertension. Unlike the Biden administration’s empty promises about drug pricing, Trump delivered tangible results that will immediately impact millions of Americans struggling with obesity and related health conditions.
Conservative Victory Against Government Healthcare Failures
This breakthrough demonstrates how effective leadership can solve problems without expanding government bureaucracy or socialist healthcare schemes. Trump’s direct negotiation approach avoided the regulatory maze that has kept life-saving treatments out of reach for ordinary Americans. The deal operates separately from the cumbersome Inflation Reduction Act processes, proving that business-minded leadership achieves better outcomes than government red tape.
The agreement particularly benefits rural communities and seniors who have been neglected by the healthcare establishment. Kennedy noted the deal serves as a “lifesaver” for Americans in food deserts, addressing real health disparities without resorting to woke identity politics or government overreach. This practical solution focuses on results rather than virtue signaling, delivering immediate relief to families struggling with obesity-related health challenges.
Sources:
Trump says Medicare can now cover weight loss drugs like Ozempic
